Opendata, web and dolomites


Sequence sPecific ELImination of shiga-Toxin E. Coli

Total Cost €


EC-Contrib. €






 SPELITEC project word cloud

Explore the words cloud of the SPELITEC project. It provides you a very rough idea of what is the project "SPELITEC" about.

complications    bacteria    drug    paediatric    stec    haemolytic    team    individualised    company    coli    clinically    gel    liquid    transfusions    capsid    pharma    strains    safe    acquisition    authorization    children    release    variants    pharmacological    patients    bacterial    first    orphan    multinational    orally    designed    treatments    eligo    complete    infections    finalise    patient    elimination    producing    eb003    dialysis    treatment    administered    populations    mutation    primary    business       spelitec    indication    selectively    mechanism    action    rehydration    uremic    background    progression    multivalent    mix    batch    unmet    receptors    hospitalized    solid    disrupting    therapeutic    toxicity    inducing    animals    fatal    toxins    plans    empts    young    stecs    spectrum    tests    receive    validated    antibodies    validate    disease    coupled    resistance    license    safety    consisting    market    launch    healthy    microbiota    medical    humans    antibiotic    nature    model    companies    clinical    initiate    toxin    eliminates    validation    exert    compound    shiga    conducting    alternative    preclinical    symptomatic   

Project "SPELITEC" data sheet

The following table provides information about the project.


Organization address
city: PARIS
postcode: 75014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙948˙250 €
 EC max contribution 2˙763˙775 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELIGO BIOSCIENCE FR (PARIS) coordinator 2˙763˙775.00


 Project objective

SPELITEC is the first treatment for Shiga toxin-producing E. coli (STEC) infections, which affects primary young children and can be fatal in 1-5% of the cases. Currently there is no validated safe treatment: hospitalized patients receive only symptomatic treatments consisting of rehydration coupled with transfusions and dialysis for haemolytic uremic complications. The SPELITEC program is designed to finalise preclinical and initiate clinical studies for elimination of STEC bacteria (Shiga-toxin producing E. coli) in paediatric populations with a dedicated product: EB003. EB003 selectively eliminates STEC bacteria early in the disease progression; it is not expected to exert any toxicity in humans or animals; it is a multivalent mix of different capsid variants allows to target the whole spectrum of clinically relevant strains and pre-empts the acquisition of resistance through mutation of bacterial receptors; it is administered orally by a liquid/gel which is patient-friendly and adapted to young children and it represents a cost-effective alternative to antibodies against Shiga toxins. Our technology is the only one allowing the specific elimination of STECs without toxin release and without disrupting microbiota and inducing antibiotic resistance. Eligo will complete early drug development, which should ensure market authorization given the orphan and unmet medical need nature of the indication, and plans to out-license the compound to an established pharma company that will launch the product on the market. The management team of Eligo has solid business and technical management experience in multinational companies and a very strong drug development background. During the Phase 2 project we will validate this new individualised therapeutic approach and mechanism of action by conducting the validation of the pharmacological model, the production of a clinical batch and the safety tests in healthy animals.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPELITEC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPELITEC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

GREEN WHS (2019)


Read More  

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

TuneFork (2018)

Mobile technology that brings personalized audio into your life

Read More